<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670019</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037462</org_study_id>
    <nct_id>NCT01670019</nct_id>
  </id_info>
  <brief_title>Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression</brief_title>
  <official_title>A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing
      antidepressant treatment in patients with major depression who have not had a complete
      therapeutic response to treatment with the antidepressant alone.

      The investigators hypothesize that added asenapine will produce greater reductions in
      depression than will added placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will undertake a 6-week, double-blind, randomized, parallel-group,
      placebo-controlled trial of adjunctive asenapine in 130 patients with MDD without psychosis
      who have had an incomplete therapeutic response to treatment with an antidepressant
      medication alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in MADRS total score</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Montgomery Asberg Depression Rating Scale (MADRS) is used by clinicians to assess the severity of depression among patients with a diagnosis of depression. It is designed to be sensitive to change resulting from antidepressant therapy.
10 items</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study completion rate</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients still taking their assigned treatment (asenapine or placebo) at the end of 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of response, remission, and sustained remission</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response will be defined as a &gt; 50% reduction from baseline in MADRS total score. Remission will be defined as a MADRS total score &lt; 7.  Sustained remission will be defined as at least two consecutive post-randomization assessments (weeks 2, 4, and 6) during which minimal depressive psychopathology (MADRS &lt; 7) is present.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Major Depressive Disorder Without Psychotic Features</condition>
  <arm_group>
    <arm_group_label>Asenapine 5-20 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1-4 tablets daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 5-20 mg daily</intervention_name>
    <description>5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID</description>
    <arm_group_label>Asenapine 5-20 mg daily</arm_group_label>
    <other_name>SAPHRIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1-4 tablets daily</intervention_name>
    <description>One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID</description>
    <arm_group_label>Placebo 1-4 tablets daily</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -130 male or female patients, 18-65 years of age, with:

          1. DSM-IV diagnosis of MDD without psychosis (single episode or recurrent) confirmed by
             the Mini-International Neuro-psychiatric Interview (MINI)

          2. MADRS total score &gt;  20, and item 1 (Apparent Sadness) score &gt; 2 at enrollment and
             randomization

          3. Inadequate therapeutic response during their current depressive episode; an
             inadequate therapeutic response will be defined as continued depressive
             psychopathology (see criterion 2) following &gt; six weeks of therapy at adequate doses
             (according to the US label) of any non-tricyclic, non-MAOI antidepressant medication

        Exclusion Criteria:

          1. Additional DSM-IV Axis I diagnoses other than Generalized Anxiety Disorder, Panic
             Disorder with or without Agoraphobia, or Social Phobia within 6 months prior to
             enrollment

          2. DSM-IV Axis II diagnoses that significantly impact the current psychiatric status

          3. Current MDD episode lasting &gt; 12 months

          4. Electroconvulsive therapy within the preceding 6 months

          5. Substance or alcohol dependence, as defined by DSM-IV criteria, within 6 months prior
             to enrollment

          6. Unstable medical illness, epilepsy, traumatic brain injury, Parkinson disease, or
             dementia (MMSE &lt;24)

          7. Risk of suicide as defined by MADRS item 10 score &gt; 4

          8. Prior failure to respond to asenapine

          9. Pregnancy or failure to use an acceptable form of birth control. Pregnancy as
             determined by serum pregnancy test at baseline

         10. Hepatic impairment and history of low WBC, by medical history and interview.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Beyer, MD</last_name>
    <phone>919-668-0209</phone>
    <email>beyer001@mc.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William H Wilson, PH.D.</last_name>
    <phone>919-575-7360</phone>
    <email>WILSO066@MC.DUKE.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon C Sebastion, MD</last_name>
      <phone>706-721-7178</phone>
      <email>ssebasti@georgiahealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Foster, MD</last_name>
      <phone>706-721-7488</phone>
      <email>afoster@georgiahealth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John L Beyer, MD</last_name>
      <phone>919-668-0209</phone>
      <email>john.beyer@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nabila Lateef, RN</last_name>
      <phone>919-684-9701</phone>
      <email>nabila.lateef@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John L Beyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Behavioral Care</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A Millet, MD</last_name>
      <phone>919-972-7700</phone>
      <email>rmillet@carolinabehavioralcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Edward S Lueth, MSW</last_name>
      <phone>919-972-7700</phone>
      <email>elueth@carolinabehavioralcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert A Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadyah J John, MD</last_name>
      <phone>252-744-2673</phone>
      <email>johnn@ecu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Richard M Bloch, PhD</last_name>
      <phone>252-744-3324</phone>
      <email>blochri@ecu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nadyah J John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Carolina Psychiatric Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy W Smith, RN</last_name>
      <phone>919-733-5229</phone>
      <email>joy.w.smith@dhhs.nc.gov</email>
    </contact>
    <contact_backup>
      <last_name>Lars F Jarskog, MD</last_name>
      <phone>919-715-9157</phone>
      <email>lars_jarskog@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lars F Jarskog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Antipsychotic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
